首页 | 本学科首页   官方微博 | 高级检索  
     


Effects of terlipressin and somatostatin on liver and thorax blood volumes in patients with cirrhosis
Authors:George Kalambokis  Spyridon Tsiouris  Epameinondas V. Tsianos  Gerasimos Baltayiannis  Barbara Pakou  Andreas Fotopoulos
Affiliation:1. 1st Division of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece;2. Hepato‐Gastroenterology Unit, Medical School, University of Ioannina, Ioannina, Greece;3. Department of Nuclear Medicine, Medical School, University of Ioannina, Ioannina, Greece
Abstract:
Background: Variceal bleeding in cirrhosis can cause liver ischaemia and deteriorate the hyperdynamic state; thus, the effects of vasoconstrictor therapy on liver blood volume (LBV) and thorax blood volume (ThBV) are important. Aim: To evaluate and compare the effects of terlipressin and somatostatin on LBV and ThBV in stable patients with cirrhosis and portal hypertension. Methods: Twenty patients were studied (Child–Pugh class A/B/C: 5/8/7). The radioactivities in the liver region (LRR) and the thorax region (ThRR) by single‐head gamma camera technique, as indicators of LBV and ThBV, respectively, and systemic haemodynamics were measured at baseline and after intravenous infusion of 2 mg of terlipressin (n=10) or somatostatin 250 mg/h after an initial bolus of 250 mg (n=10). Results: LRR and ThRR decreased significantly with increasing severity of cirrhosis. Thirty minutes after terlipressin infusion, LRR and ThRR increased by 7.8 ± 4.4% (NS) and 14 ± 5.3% (P=0.01) compared with baseline values; the increase in ThRR was significantly related to the increase in LRR (r=0.682, P=0.03). In contrast, somatostatin reduced LRR and ThRR by 13.3 ± 6.5% (P=0.07) and 1 ± 4% (NS) respectively. LRR and ThRR increased significantly in the terlipressin group compared with the somatostatin group (P=0.01 and P=0.02 respectively). Terlipressin reduced cardiac output and heart rate (both P=0.01) and increased the mean arterial pressure (MAP) and systemic vascular resistance (P=0.009 and P=0.002 respectively); MAP decreased after somatostatin infusion (P=0.03). Conclusions: Terlipressin, but not somatostatin, maintains LBV, increases ThBV and improves the hyperdynamic state in cirrhosis. These effects can be beneficial in variceal bleeding, particularly in patients with advanced liver disease.
Keywords:cirrhosis  gamma‐camera technique  liver blood volume  somatostatin  terlipressin  thorax blood volume
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号